Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Calgary, Alberta--(Newsfile Corp. - August 22, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. "We are very pleased to announce...
2023-08-22 9:00 AM EDT
Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference
Calgary, Alberta--(Newsfile Corp. - July 10, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has been selected to present the Company's scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's Association International Conference (AAIC) Sunday, July 16, 2023: 7:00 AM – 11:55 PM...
2023-07-10 4:30 PM EDT
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials
Calgary, Alberta--(Newsfile Corp. - April 20, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. "We are pleased to report we have now completed treating both rats and dogs with...
2023-04-20 9:00 AM EDT
Marvel Commences Final Study Required Prior to Initiating Human Trials
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204. "This dog study is the last of the two key primary animal studies we need to complete before entering phase 1...
2023-03-21 9:00 AM EDT
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
Calgary, Alberta--(Newsfile Corp. - March 9, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204. "This rat study, along with the GLP study on dogs, are the last two key studies we need to complete before...
2023-03-09 9:00 AM EST
Marvel Biosciences Announces Closing of First Tranche of Debenture Offering
Calgary, Alberta--(Newsfile Corp. - February 24, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures ("Debentures") for gross proceeds of $1,000,000 (the "Private Placement"), subject to final approval of the TSX Venture Exchange. The Debentures bear interest at the rate of eight percent (8%) per annum, payable annually and...
2023-02-24 5:43 PM EST
Marvel Biosciences Announces Proposed Debenture Offering
Calgary, Alberta--(Newsfile Corp. - February 15, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $1,500,000 (the "Private Placement"). The Debentures will bear interest at the rate of eight percent (8%) per annum, payable annually and will mature on the date that is three years from the closing date....
2023-02-15 9:00 AM EST
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company " or "Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active pharmaceutical ingredient (API) of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The cGMP...
2023-01-06 9:00 AM EST
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies. "We are looking forward to initiating the 4-week...
2023-01-03 9:00 AM EST
Marvel Biosciences Announces Letter Agreement for Market Stabilization and Liquidity Services
Calgary, Alberta--(Newsfile Corp. - December 23, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the "Consulting Agreement") with Mr. Adam Smith of Red Cloud Securities Inc. ("Red Cloud") to support Marvel's market stabilization and liquidity activities. Marvel entered into the...
2022-12-23 4:30 PM EST
Marvel Biosciences Announces Stock Option Grant
Calgary, Alberta--(Newsfile Corp. - December 20, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to a director to acquire 200,000 common shares in the capital of the Company at an exercise price of $0.135 being the closing price of the Company's common shares on the TSX Venture Exchange...
2022-12-20 9:00 AM EST
Marvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - December 12, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204. To date, the Company's MB-204 has shown positive and promising data addressing depression, anxiety as well as its potential benefit in protecting patient's vital organs while going...
2022-12-12 9:00 AM EST
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials. "We have significantly de-risked the development of our lead drug candidate MB-204 and...
2022-12-07 9:00 AM EST
Marvel Biosciences Announces Director Appointment and Resignation
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined its Board of Directors. Babak Pedram, Director Mr. Pedram brings a vast degree of business, capital markets and scientific experience to Marvel's Board of Directors. He is a seasoned capital market professional with...
2022-11-24 5:36 PM EST
Marvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum
Calgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum. "We are seeing great momentum being built around our lead drug candidate...
2022-11-22 9:00 AM EST
Marvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies
Calgary, Alberta--(Newsfile Corp. - November 14, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed Istradefylline in a head-to-head pre-clinical and in depressive and anti-anxiety studies. Istradefylline is the only US FDA approved A2a receptor...
2022-11-14 9:00 AM EST
Marvel Biosciences' Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer's Disease and Depression
Calgary, Alberta--(Newsfile Corp. - November 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced today that in a pre-clinical mouse study conducted by the Company, its lead drug candidate MB-204 successfully entered the brain and occupied its target, the adenosine A2a receptor. The adenosine A2a receptor has been validated by numerous scientific studies that it plays a significant role...
2022-11-07 9:00 AM EST
Marvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer's Further Advancing Towards FDA Phase I Human Trials
Calgary, Alberta--(Newsfile Corp. - November 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion (SAD) formulation of MB-204 by Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The engineering run material will be utilized to support the ongoing toxicology studies of MB-204 being...
2022-11-01 9:00 AM EDT
Marvel Biosciences Advances Closer to Human Trials After the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company's lead drug candidate low toxicity characteristic. "We have now completed and further validated MB-204's safety profile through this recent dog toxicology study in addition to our recently press released toxicology study in...
2022-10-25 9:00 AM EDT
Marvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
Calgary, Alberta--(Newsfile Corp. - October 17, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity. MB-204 is the Company's lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti-Parkinson's disease drug) and is a blood brain barrier permeable adenosine A2a receptor antagonist. Marvel is developing...
2022-10-17 9:00 AM EDT